Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Carcinoma 1

Interventions

pembrolizumab 3temsirolimus 1spartalizumab 1poly ICLC 1patritumab 1durvalumab 1atezolizumab 1advexin 1Tetanus Toxoid 1Sunitinib 1Rifampin 1Radiation 1Nivolumab 1Midazolam 1Ketoconazole 1Ipilimumab 1Interleukin-15 1Brentuximab Vedotin 1Blood Specimen Collection 1Axitinib 13-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 12,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 11-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Tetanus Toxoid × Lymphoid × Clear all
NCT01644968 2022-05-17

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Providence Health & Services

Phase 1 Completed
30 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡